Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate
BERLIN, Germany, April 26, 2021 / B3C newswire / --ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale. ProBioGen will now advance the development of Asher's lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic. Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies with a new level of selectivity for the potential treatment of cancer, autoimmune and infectious diseases.